+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 65Years
All Genders
Healthy Volunteers
ID07532655

Randomized, Double-Blind Study of SYH2082 Injection to Evaluate Safety and Drug Effects in Healthy Adults with Overweight or Obesity

Led by CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · Updated on 2026-10-23

60

Participants Needed

1

Research Sites

14 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and tolerability of single and multiple doses of SYH2082 Injection in healthy adults aged 18 to 65 years who are overweight or obese. This phase 1, randomized, double-blind, placebo-controlled study aims to understand how the body processes the drug pharmacokinetics and its effects pharmacodynamics while carefully monitoring any adverse events. Participants will receive either SYH2082 Injection or a placebo under controlled conditions. The study includes single ascending dose and multiple ascending dose periods, following a dose escalation protocol. Treatments are administered by subcutaneous injection in the abdomen. The study follows a detailed schedule up to 85 days, with screening periods extending up to 35 days before dosing. Throughout the study, participants will undergo frequent assessments including physical exams, vital signs, blood tests for drug levels and immune response, electrocardiograms, and metabolic measurements such as fasting glucose and insulin. Researchers will track adverse events to evaluate safety and tolerability. The total participation duration varies with the dose schedule but includes follow-ups up to 85 days after dosing completion.

CONDITIONS

Brief Title

A Single Ascending Dose and Multiple Ascending Doses Study of SYH2082 Injection in Healthy Participants

Research Team

C

Clinical Trials Information Group officer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here